Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Angiogenesis
Published in: Angiogenesis 3/2012

Open Access 01-09-2012 | Original Paper

Resveratrol and its synthetic derivatives exert opposite effects on mesothelial cell-dependent angiogenesis via modulating secretion of VEGF and IL-8/CXCL8

Authors: Justyna Mikuła-Pietrasik, Angelika Kuczmarska, Małgorzata Kucińska, Marek Murias, Marcin Wierzchowski, Marek Winckiewicz, Ryszard Staniszewski, Andrzej Bręborowicz, Krzysztof Książek

Published in: Angiogenesis | Issue 3/2012

Login to get access

Abstract

We examined the effect of resveratrol (RVT) and its two derivatives (3,3′,4,4′-tetrahydroxy-trans-stilbene and 3,3′,4,4′,5,5′-hexahydroxy-trans-stilbene) on human peritoneal mesothelial cell (HPMC)-dependent angiogenesis in vitro. To this end, angiogenic activity of endothelial cells (HUVEC, HMVEC, and HMEC-1) was monitored upon their exposure to conditioned medium (CM) from young and senescent HPMCs treated with stilbenes or to stilbenes themselves. Results showed that proliferation and migration of endothelial cells were inhibited in response to indirect (HPMC-dependent) or direct RVT activity. This effect was associated with decreased secretion of VEGF and IL-8/CXCL8 by HPMCs treated with RVT, which confirmed the experiments with recombinant forms of these angiogenic agents. Angiogenic activity of endothelial cells treated with CM from HPMCs exposed to RVT analogues was more effective. Improved migration was particularly evident in cells exposed to CM from senescent HPMCs. Upon direct treatment, RVT derivatives stimulated proliferation (but not migration) of HUVECs, and failed to affect the behaviour of HMVEC and HMEC-1 cells. These compounds stimulated production of VEGF and IL-8/CXCL8 by HPMCs. Studies with neutralizing antibodies against angiogenic factors revealed that augmented angiogenic reactions of endothelial cells exposed to CM from HPMC treated with RVT analogues were related to enhanced production of VEGF and IL-8/CXCL8. Collectively, these findings indicate that RVT and its synthetic analogues divergently alter the secretion of the angiogenic factors by HPMCs, and thus modulate HPMC-dependent angiogenic responses in the opposite directions. This may have implications for the attempts of practical employment of the stilbenes for treatment of pathologies proceeding with abnormal vascularisation of the peritoneal tissue.
Literature
1.
Strobel T, Cannistra SA (1999) Beta1-integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro. Gynecol Oncol 73:362–367PubMedCrossRef
2.
Lessan K, Aguiar DJ, Oegema T, Siebenson L, Skubitz AP (1999) CD44 and beta1 integrin mediate ovarian carcinoma cell adhesion to peritoneal mesothelial cells. Am J Pathol 154:1525–1537PubMedCrossRef
3.
Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4–6PubMedCrossRef
4.
Gerber SA, Rybalko VY, Bigelow CE, Lugade AA, Foster TH, Frelinger JG, Lord EM (2006) Preferential attachment of peritoneal tumor metastases to omental immune aggregates and possible role of a unique vascular microenvironment in metastatic survival and growth. Am J Pathol 169:1739–1752PubMedCrossRef
5.
Ksiazek K, Mikula-Pietrasik J, Jorres A, Witowski J (2008) Oxidative stress-mediated early senescence contributes to the short replicative life span of human peritoneal mesothelial cells. Free Radic Biol Med 45:460–467PubMedCrossRef
6.
Ksiazek K, Mikula-Pietrasik J, Korybalska K, Dworacki G, Jorres A, Witowski J (2009) Senescent peritoneal mesothelial cells promote ovarian cancer cell adhesion: the role of oxidative stress-induced fibronectin. Am J Pathol 174:1230–1240PubMedCrossRef
7.
Ksiazek K, Mikula-Pietrasik J, Catar R, Dworacki G, Winckiewicz M, Frydrychowicz M, Dragun D, Staniszewski R, Jorres A, Witowski J (2010) Oxidative stress-dependent increase in ICAM-1 expression promotes adhesion of colorectal and pancreatic cancers to the senescent peritoneal mesothelium. Int J Cancer 127:293–303PubMed
8.
Ksiazek K, Jorres A, Witowski J (2008) Senescence induces a proangiogenic switch in human peritoneal mesothelial cells. Rejuvenation Res 11:681–683PubMedCrossRef
9.
Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y (2004) Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 24:2783–2840PubMed
10.
Rezk YA, Balulad SS, Keller RS, Bennett JA (2006) Use of resveratrol to improve the effectiveness of cisplatin and doxorubicin: study in human gynecologic cancer cell lines and in rodent heart. Am J Obstet Gynecol 194:e23–e26PubMedCrossRef
11.
Chen Y, Tseng SH (2007) Review. Pro- and anti-angiogenesis effects of resveratrol. In Vivo 21:365–370PubMed
12.
Kaga S, Zhan L, Matsumoto M, Maulik N (2005) Resveratrol enhances neovascularization in the infarcted rat myocardium through the induction of thioredoxin-1, heme oxygenase-1 and vascular endothelial growth factor. J Mol Cell Cardiol 39:813–822PubMedCrossRef
13.
Robich MP, Osipov RM, Nezafat R, Feng J, Clements RT, Bianchi C, Boodhwani M, Coady MA, Laham RJ, Sellke FW (2010) Resveratrol improves myocardial perfusion in a swine model of hypercholesterolemia and chronic myocardial ischemia. Circulation 122:S142–S149PubMedCrossRef
14.
Srivastava RK, Unterman TG, Shankar S (2010) FOXO transcription factors and VEGF neutralizing antibody enhance antiangiogenic effects of resveratrol. Mol Cell Biochem 337:201–212PubMedCrossRef
15.
Kimura Y, Sumiyoshi M, Baba K (2008) Antitumor activities of synthetic and natural stilbenes through antiangiogenic action. Cancer Sci 99:2083–2096PubMedCrossRef
16.
Garvin S, Ollinger K, Dabrosin C (2006) Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Lett 231:113–122PubMedCrossRef
17.
Chen JC, Chen Y, Lin JH, Wu JM, Tseng SH (2006) Resveratrol suppresses angiogenesis in gliomas: evaluation by color Doppler ultrasound. Anticancer Res 26:1237–1245PubMed
18.
Murias M, Jager W, Handler N, Erker T, Horvath Z, Szekeres T, Nohl H, Gille L (2005) Antioxidant, prooxidant and cytotoxic activity of hydroxylated resveratrol analogues: structure-activity relationship. Biochem Pharmacol 69:903–912PubMedCrossRef
19.
Murias M, Handler N, Erker T, Pleban K, Ecker G, Saiko P, Szekeres T, Jager W (2004) Resveratrol analogues as selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationship. Bioorg Med Chem 12:5571–5578PubMedCrossRef
20.
Murias M, Miksits M, Aust S, Spatzenegger M, Thalhammer T, Szekeres T, Jaeger W (2008) Metabolism of resveratrol in breast cancer cell lines: impact of sulfotransferase 1A1 expression on cell growth inhibition. Cancer Lett 261:172–182PubMedCrossRef
21.
Yung S, Li FK, Chan TM (2006) Peritoneal mesothelial cell culture and biology. Perit Dial Int 26:162–173PubMed
22.
Witowski J, Korybalska K, Wisniewska J, Breborowicz A, Gahl GM, Frei U, Passlick-Deetjen J, Jorres A (2000) Effect of glucose degradation products on human peritoneal mesothelial cell function. J Am Soc Nephrol 11:729–739PubMed
23.
Kim S, Bell K, Mousa SA, Varner JA (2000) Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. Am J Pathol 156:1345–1362PubMedCrossRef
24.
Mizukami Y, Jo WS, Duerr EM, Gala M, Li J, Zhang X, Zimmer MA, Iliopoulos O, Zukerberg LR, Kohgo Y, Lynch MP, Rueda BR, Chung DC (2005) Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat Med 11:992–997PubMed
25.
Shibata T, Imaizumi T, Matsumiya T, Tamo W, Hatakeyama M, Yoshida H, Munakata H, Fukuda I, Satoh K (2003) Effect of MG132, a proteasome inhibitor, on the expression of growth related oncogene protein-alpha in human umbilical vein endothelial cells. Cytokine 24:67–73PubMedCrossRef
26.
Li S, Takeuchi F, Wang JA, Fuller C, Pacheco-Rodriguez G, Moss J, Darling TN (2005) MCP-1 overexpressed in tuberous sclerosis lesions acts as a paracrine factor for tumor development. J Exp Med 202:617–624PubMedCrossRef
27.
28.
Bian XW, Chen JH, Jiang XF, Bai JS, Wang QL, Zhang X (2004) Angiogenesis as an immunopharmacologic target in inflammation and cancer. Int Immunopharmacol 4:1537–1547PubMedCrossRef
29.
Marchetti M, Vignoli A, Russo L, Balducci D, Pagnoncelli M, Barbui T, Falanga A (2008) Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin. Thromb Res 121:637–645PubMedCrossRef
30.
Bijnsdorp IV, Capriotti F, Kruyt FA, Losekoot N, Fukushima M, Griffioen AW, Thijssen VL, Peters GJ (2011) Thymidine phosphorylase in cancer cells stimulates human endothelial cell migration and invasion by the secretion of angiogenic factors. Br J Cancer 104:1185–1192PubMedCrossRef
31.
Boisen L, Drasbek KR, Pedersen AS, Kristensen P (2010) Evaluation of endothelial cell culture as a model system of vascular ageing. Exp Gerontol 45:779–787PubMedCrossRef
32.
Nanobashvili J, Jozkowicz A, Neumayer C, Fugl A, Sporn E, Polterauer P, Huk I (2003) Comparison of angiogenic potential of human microvascular endothelial cells and human umbilical vein endothelial cells. Eur Surg 35:214–218CrossRef
33.
Nunez MJ, Novio S, Balboa J, Seoane J, Suarez JA, Freire-Garabal M (2010) Effects of resveratrol on expression of vascular endothelial growth factor in human gingival fibroblasts stimulated by periodontal pathogens. Acta Odontol Scand 68:239–247PubMedCrossRef
34.
Knobloch J, Sibbing B, Jungck D, Lin Y, Urban K, Stoelben E, Strauch J, Koch A (2010) Resveratrol impairs the release of steroid-resistant inflammatory cytokines from human airway smooth muscle cells in chronic obstructive pulmonary disease. J Pharmacol Exp Ther 335:788–798PubMedCrossRef
35.
Gauliard B, Grieve D, Wilson R, Crozier A, Jenkins C, Mullen WD, Lean M (2008) The effects of dietary phenolic compounds on cytokine and antioxidant production by A549 cells. J Med Food 11:382–384PubMedCrossRef
36.
Trapp V, Parmakhtiar B, Papazian V, Willmott L, Fruehauf JP (2010) Anti-angiogenic effects of resveratrol mediated by decreased VEGF and increased TSP1 expression in melanoma-endothelial cell co-culture. Angiogenesis 13:305–315PubMedCrossRef
37.
Belleri M, Ribatti D, Nicoli S, Cotelli F, Forti L, Vannini V, Stivala LA, Presta M (2005) Antiangiogenic and vascular-targeting activity of the microtubule-destabilizing trans-resveratrol derivative 3,5,4′-trimethoxystilbene. Mol Pharmacol 67:1451–1459PubMedCrossRef
38.
Bertl E, Becker H, Eicher T, Herhaus C, Kapadia G, Bartsch H, Gerhauser C (2004) Inhibition of endothelial cell functions by novel potential cancer chemopreventive agents. Biochem Biophys Res Commun 325:287–295PubMedCrossRef
39.
Cao L, Liu H, Lam DS, Yam GH, Pang CP (2010) In vitro screening for angiostatic potential of herbal chemicals. Invest Ophthalmol Vis Sci 51:6658–6664PubMedCrossRef
40.
Wang H, Zhou H, Zou Y, Liu Q, Guo C, Gao G, Shao C, Gong Y (2010) Resveratrol modulates angiogenesis through the GSK3beta/beta-catenin/TCF-dependent pathway in human endothelial cells. Biochem Pharmacol 80:1386–1395PubMedCrossRef
41.
Stivala LA, Savio M, Carafoli F, Perucca P, Bianchi L, Maga G, Forti L, Pagnoni UM, Albini A, Prosperi E, Vannini V (2001) Specific structural determinants are responsible for the antioxidant activity and the cell cycle effects of resveratrol. J Biol Chem 276:22586–22594PubMedCrossRef
42.
Horvath Z, Murias M, Saiko P, Erker T, Handler N, Madlener S, Jaeger W, Grusch M, Fritzer-Szekeres M, Krupitza G, Szekeres T (2006) Cytotoxic and biochemical effects of 3,3′,4,4′,5,5′-hexahydroxystilbene, a novel resveratrol analog in HL-60 human promyelocytic leukemia cells. Exp Hematol 34:1377–1384PubMedCrossRef
43.
Saiko P, Pemberger M, Horvath Z, Savinc I, Grusch M, Handler N, Erker T, Jaeger W, Fritzer-Szekeres M, Szekeres T (2008) Novel resveratrol analogs induce apoptosis and cause cell cycle arrest in HT29 human colon cancer cells: inhibition of ribonucleotide reductase activity. Oncol Rep 19:1621–1626PubMed
44.
Lin CM, Chang H, Chen YH, Li SY, Wu IH, Chiu JH (2006) Protective role of wogonin against lipopolysaccharide-induced angiogenesis via VEGFR-2, not VEGFR-1. Int Immunopharmacol 6:1690–1698PubMedCrossRef
45.
Chen Y, Zhang YX, Li MH, Zhao WM, Shi YH, Miao ZH, Zhang XW, Lin LP, Ding J (2005) Antiangiogenic activity of 11,11′-dideoxyverticillin, a natural product isolated from the fungus Shiraia bambusicola. Biochem Biophys Res Commun 329:1334–1342PubMedCrossRef
46.
Kanno S, Oda N, Abe M, Terai Y, Ito M, Shitara K, Tabayashi K, Shibuya M, Sato Y (2000) Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells. Oncogene 19:2138–2146PubMedCrossRef
47.
Murias M, Luczak MW, Niepsuj A, Krajka-Kuzniak V, Zielinska-Przyjemska M, Jagodzinski PP, Jager W, Szekeres T, Jodynis-Liebert J (2008) Cytotoxic activity of 3,3′,4,4′,5,5′-hexahydroxystilbene against breast cancer cells is mediated by induction of p53 and downregulation of mitochondrial superoxide dismutase. Toxicol In Vitro 22:1361–1370PubMedCrossRef
48.
Ivison SM, Wang C, Himmel ME, Sheridan J, Delano J, Mayer ML, Yao Y, Kifayet A, Steiner TS (2010) Oxidative stress enhances IL-8 and inhibits CCL20 production from intestinal epithelial cells in response to bacterial flagellin. Am J Physiol Gastrointest Liver Physiol 299:G733–G741PubMedCrossRef
49.
Kosmidou I, Xagorari A, Roussos C, Papapetropoulos A (2001) Reactive oxygen species stimulate VEGF production from C(2)C(12) skeletal myotubes through a PI3 K/Akt pathway. Am J Physiol Lung Cell Mol Physiol 280:L585–L592PubMed
50.
Witowski J, Ksiazek K, Jorres A (2008) Glucose-induced mesothelial cell senescence and peritoneal neoangiogenesis and fibrosis. Perit Dial Int 28(Suppl 5):S34–S37PubMed
51.
Jayne D (2007) Molecular biology of peritoneal carcinomatosis. Cancer Treat Res 134:21–33PubMed
52.
Kim YL (2009) Update on mechanisms of ultrafiltration failure. Perit Dial Int 29(Suppl 2):S123–S127PubMed
53.
Ha H, Cha MK, Choi HN, Lee HB (2002) Effects of peritoneal dialysis solutions on the secretion of growth factors and extracellular matrix proteins by human peritoneal mesothelial cells. Perit Dial Int 22:171–177PubMed
54.
Rahman I, Biswas SK, Kirkham PA (2006) Regulation of inflammation and redox signaling by dietary polyphenols. Biochem Pharmacol 72:1439–1452PubMedCrossRef
55.
Davies SJ, Mushahar L, Yu Z, Lambie M (2011) Determinants of peritoneal membrane function over time. Semin Nephrol 31:172–182PubMedCrossRef
56.
Ksiazek K, Breborowicz A, Jorres A, Witowski J (2007) Oxidative stress contributes to accelerated development of the senescent phenotype in human peritoneal mesothelial cells exposed to high glucose. Free Radic Biol Med 42:636–641PubMedCrossRef
57.
Yao Q, Pawlaczyk K, Ayala ER, Styszynski A, Breborowicz A, Heimburger O, Qian JQ, Stenvinkel P, Lindholm B, Axelsson J (2008) The role of the TGF/Smad signaling pathway in peritoneal fibrosis induced by peritoneal dialysis solutions. Nephron Exp Nephrol 109:e71–e78PubMedCrossRef
58.
Ksiazek K, Korybalska K, Jorres A, Witowski J (2007) Accelerated senescence of human peritoneal mesothelial cells exposed to high glucose: the role of TGF-beta1. Lab Invest 87:345–356PubMed
59.
Paulitschke V, Schicher N, Szekeres T, Jager W, Elbling L, Riemer AB, Scheiner O, Trimurtulu G, Venkateswarlu S, Mikula M, Swoboda A, Fiebiger E, Gerner C, Pehamberger H, Kunstfeld R (2010) 3,3′,4,4′,5,5′-hexahydroxystilbene impairs melanoma progression in a metastatic mouse model. J Invest Dermatol 130:1668–1679PubMedCrossRef
Metadata
Title
Resveratrol and its synthetic derivatives exert opposite effects on mesothelial cell-dependent angiogenesis via modulating secretion of VEGF and IL-8/CXCL8
Authors
Justyna Mikuła-Pietrasik
Angelika Kuczmarska
Małgorzata Kucińska
Marek Murias
Marcin Wierzchowski
Marek Winckiewicz
Ryszard Staniszewski
Andrzej Bręborowicz
Krzysztof Książek
Publication date
01-09-2012
Publisher
Springer Netherlands
Published in
Angiogenesis / Issue 3/2012
Print ISSN: 0969-6970
Electronic ISSN: 1573-7209
DOI
https://doi.org/10.1007/s10456-012-9266-0

Other articles of this Issue 3/2012

Angiogenesis 3/2012 Go to the issue

Erratum

Erratum to: The elevation in maternal anti-angiogenic factors is independent of markers of neutrophil activation and systemic inflammation in preeclampsia

Original Paper

P2Y4 nucleotide receptor: a novel actor in post-natal cardiac development

Original Paper

Equal modulation of endothelial cell function by four distinct tissue-specific mesenchymal stem cells

Original Paper

Quantitative assessment of tumor angiogenesis using real-time motion-compensated contrast-enhanced ultrasound imaging

Original Paper

Usnic acid inhibits breast tumor angiogenesis and growth by suppressing VEGFR2-mediated AKT and ERK1/2 signaling pathways

Original Paper

Dual action of TGF-β induces vascular growth in vivo through recruitment of angiogenic VEGF-producing hematopoietic effector cells
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits